Synthesis, antitumor evaluation and molecular docking studies of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives. 2016

Feng Xu, and Zhen-Zhen Yang, and Jun-Rong Jiang, and Wan-Gui Pan, and Xiao-le Yang, and Jian-Yong Wu, and Yan Zhu, and John Wang, and Qi-Yang Shou, and Han-Gui Wu
Chemical Pharmaceutical Research Institute, Taizhou Vocational & Technical College, Taizhou 318000, PR China. Electronic address: xufeng901@126.com.

A series of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives have been synthesized and evaluated for their antitumor activities. These compounds exhibited potent antiproliferative activities against MCF-7, Bewo and HL-60 cells and c-Met kinase inhibitory activities. Three compounds were highly effective against MCF-7, Bewo and HL-60 cells with IC50 values in 1.09-2.24μM. Molecular docking was further performed to study the inhibitor-c-Met kinase interactions, and the results show that compound 4j was potently bound to the c-Met kinase with three hydrogen bonds. The further research on acute toxicity and in vivo antitumor activity of compound 4j to ICR (Institute of Cancer Research) mice were carried out, and found 4j with a certain toxicity but good efficacy in vivo. Based on the preliminary results, it is deduced that compound 4j with potent c-Met kinase inhibitory activity may be a potential anticancer agent.

UI MeSH Term Description Entries
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006574 Heterocyclic Compounds, 2-Ring A class of heterocyclic compounds that include a two-ring fused structure. Both aromatic and non-aromatic ring structures are included in this category. Fused Heterocyclic Compounds, Two-Ring,Two Ring Heterocyclic Compounds,2-Ring Heterocyclic Compounds,Fused Heterocyclic Compounds, Two Ring,Heterocyclic Compounds, 2 Ring
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D061986 MCF-7 Cells An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.) MCF7 Cells,Michigan Cancer Foundation 7 Cells,Cell, MCF-7,Cell, MCF7,Cells, MCF-7,Cells, MCF7,MCF 7 Cells,MCF-7 Cell,MCF7 Cell

Related Publications

Feng Xu, and Zhen-Zhen Yang, and Jun-Rong Jiang, and Wan-Gui Pan, and Xiao-le Yang, and Jian-Yong Wu, and Yan Zhu, and John Wang, and Qi-Yang Shou, and Han-Gui Wu
July 2010, Journal of hazardous materials,
Feng Xu, and Zhen-Zhen Yang, and Jun-Rong Jiang, and Wan-Gui Pan, and Xiao-le Yang, and Jian-Yong Wu, and Yan Zhu, and John Wang, and Qi-Yang Shou, and Han-Gui Wu
April 2020, Scientific reports,
Feng Xu, and Zhen-Zhen Yang, and Jun-Rong Jiang, and Wan-Gui Pan, and Xiao-le Yang, and Jian-Yong Wu, and Yan Zhu, and John Wang, and Qi-Yang Shou, and Han-Gui Wu
October 2022, Molecules (Basel, Switzerland),
Feng Xu, and Zhen-Zhen Yang, and Jun-Rong Jiang, and Wan-Gui Pan, and Xiao-le Yang, and Jian-Yong Wu, and Yan Zhu, and John Wang, and Qi-Yang Shou, and Han-Gui Wu
January 2014, Organic letters,
Feng Xu, and Zhen-Zhen Yang, and Jun-Rong Jiang, and Wan-Gui Pan, and Xiao-le Yang, and Jian-Yong Wu, and Yan Zhu, and John Wang, and Qi-Yang Shou, and Han-Gui Wu
December 2018, Chemistry, an Asian journal,
Feng Xu, and Zhen-Zhen Yang, and Jun-Rong Jiang, and Wan-Gui Pan, and Xiao-le Yang, and Jian-Yong Wu, and Yan Zhu, and John Wang, and Qi-Yang Shou, and Han-Gui Wu
February 2021, Molecular diversity,
Feng Xu, and Zhen-Zhen Yang, and Jun-Rong Jiang, and Wan-Gui Pan, and Xiao-le Yang, and Jian-Yong Wu, and Yan Zhu, and John Wang, and Qi-Yang Shou, and Han-Gui Wu
January 2021, Bioorganic & medicinal chemistry,
Feng Xu, and Zhen-Zhen Yang, and Jun-Rong Jiang, and Wan-Gui Pan, and Xiao-le Yang, and Jian-Yong Wu, and Yan Zhu, and John Wang, and Qi-Yang Shou, and Han-Gui Wu
December 2013, Bioorganic & medicinal chemistry letters,
Feng Xu, and Zhen-Zhen Yang, and Jun-Rong Jiang, and Wan-Gui Pan, and Xiao-le Yang, and Jian-Yong Wu, and Yan Zhu, and John Wang, and Qi-Yang Shou, and Han-Gui Wu
July 2021, Antibiotics (Basel, Switzerland),
Feng Xu, and Zhen-Zhen Yang, and Jun-Rong Jiang, and Wan-Gui Pan, and Xiao-le Yang, and Jian-Yong Wu, and Yan Zhu, and John Wang, and Qi-Yang Shou, and Han-Gui Wu
June 2012, ChemMedChem,
Copied contents to your clipboard!